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Abstract
Background: Several strategies to optimise the use of antibiotics have been developed. Most of these interventions can
be classified as educational or restrictive. Restrictive measures are considered to be more effective, but the enforcement
of these measures may be difficult and lead to conflicts with prescribers. Any intervention should be aimed at targets
with the highest impact on antibiotic prescribing. The aim of the present study was to assess the adequacy of empirical
and adjusted antibiotic therapies in a Swiss university hospital where no antibiotic use restrictions are enforced, and to
identify risk factors for inadequate treatment and targets for intervention.
Methods: A prospective observational study was performed during 9 months. All patients admitted through the
emergency department who received an antibiotic therapy within 24 hours of admission were included. Data on
demographic characteristics, diagnoses, comorbidities, systemic inflammatory response syndrome (SIRS) parameters,
microbiological tests, and administered antibiotics were collected prospectively. Antibiotic therapy was considered
adequate if spectrum, dose, application modus, and duration of therapy were appropriate according to local
recommendations or published guidelines.
Results: 2943 admitted patients were evaluated. Of these, 572 (19.4%) received antibiotics within 24 hours and 539
(94%) were analysed in detail. Empirical antibiotic therapy was inadequate in 121 patients (22%). Initial therapy was
adjusted in 168 patients (31%). This adjusted antibiotic therapy was inadequate in 46 patients (27%). The main reason for
inadequacy was the use of antibiotics with unnecessarily broad spectrum (24% of inadequate empirical, and 52% of
inadequate adjusted therapies). In 26% of patients with inadequate adjusted therapy, antibiotics used were either
ineffective against isolated pathogenic bacteria or antibiotic therapy was continued despite negative results of
microbiological investigations.
Conclusion: The rate of inadequate antibiotic therapies was similar to the rates reported from other institutions despite
the absence of a restrictive antibiotic policy. Surprisingly, adjusted antibiotic therapies were more frequently
inappropriate than empirical therapies. Interventions aiming at improving antibiotic prescribing should focus on both
initial empirical therapy and streamlining and adjustment of therapy once microbiological results become available.
Published: 26 March 2007
BMC Infectious Diseases 2007, 7:21 doi:10.1186/1471-2334-7-21
Received: 9 May 2006
Accepted: 26 March 2007
This article is available from: http://www.biomedcentral.com/1471-2334/7/21
© 2007 Mettler et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2007, 7:21 http://www.biomedcentral.com/1471-2334/7/21
Page 2 of 10
(page number not for citation purposes)
Background
Antibiotic resistance of bacteria is an increasing, world-
wide problem [1-3]. The use of antibiotics is an important
factor contributing to the emergence of antibiotic-resist-
ant bacteria [4,5], and it is well known, that a large pro-
portion of administered antibiotics is prescribed without
proper indication [6-11]. Published rates of inappropriate
antibiotic use are as high as 41% to 91% [6,11].
Several strategies to optimise the use of antibiotics, often
referred to as antibiotic stewardship programs, have been
developed. These interventions can be classified into two
main categories: educational, and restrictive or coercive
[12]. Both types of intervention may be useful in reducing
the amount of prescribed antibiotics and costs of therapy
while maintaining quality of care [13,14]. However,
restrictive measures are considered to be more effective
and to have a longer lasting impact than educational strat-
egies [12].
The aim of the present study was to assess the adequacy of
empirical and adjusted antibiotic therapies at a Swiss uni-
versity hospital where no restrictive measures regarding
antibiotic use are in place, and to identify risk factors for
inadequate treatment and targets for intervention.
Methods
The study was conducted prospectively during a period of
9 months (November 17, 2003 – July 31, 2004) on alter-
nating weeks at the University Hospital Basel, a 700-bed
hospital in Northwestern Switzerland providing primary
and tertiary care for adult patients. The emergency depart-
ment of this hospital handles all emergencies except gyne-
cological/obstetrical, ophthalmologic and pediatric ones.
In 2004, 38.5% of all in-patients were admitted through
the emergency department.
Antibiotics available within the hospital are listed in the
drug formulary. All drugs included in the formulary can
be prescribed without restrictions. In addition, the hospi-
tal pharmacy provides drugs which are not in the formu-
lary upon request, although physicians are encouraged to
use listed agents. Written local recommendations for the
antibiotic treatment of the most common infectious dis-
eases are available to all hospital physicians on the
intranet and as a booklet. These internal guidelines
include recommendations on diagnosis and treatment of
pneumonia, sepsis, endocarditis, urinary tract infections,
infections of the central nervous system, intravascular
catheter-related infections, fever in neutropenic patients,
and on empirical therapy in patients with suspected infec-
tion. The guidelines focus mainly on the choice and on
the dose of the antibiotic. Recommendations on duration
of therapy (and on duration of i.v. therapy) are provided
for some indications (e.g. endocarditis, meningitis, intra-
vascular catheter-related infections, urinary tract infec-
tions). There are no general recommendations for the
switch from i.v. to p.o. An active infectious diseases con-
sultation service is present in the hospital and has a close
collaboration with the microbiology laboratory. In addi-
tion, weekly infectious diseases rounds are held on all
medicine wards, on the bone marrow transplant unit and
on the intensive care units.
All patients admitted to the University Hospital Basel
through the emergency department during the mentioned
period were included in the study and prospectively fol-
lowed-up for the use of therapeutic antibiotics. Data of all
patients receiving an antibiotic therapy within 24 hours of
admission were further analysed. These patients began an
antibiotic treatment within 24 hours of admission or con-
tinued an antibiotic treatment started in another hospital.
They were treated as in-patients on the emergency depart-
ment ward, or transferred to the departments of internal
medicine (including neurology and geriatrics), surgery, or
to an intensive care unit, either directly after admission, or
subsequently from the emergency department ward. The
following patients were excluded: patients admitted to the
eight-bed acute psychiatric intervention unit, to dermatol-
ogy, ophthalmology, gynecology/obstetrics, or otorhi-
nolaryngology wards; patients given antibiotics for
prophylaxis or for Helicobacter pylori eradication; patients
who started antibiotic therapies as out-patients and
patients transferred to another hospital within 48 hours of
admission.
Information on demographics, admission diagnoses,
empirical and adjusted antibiotic therapies, duration of
therapy, specimens submitted for bacteriological testing,
results of microbiological investigations, involvement of
infectious diseases consultants, Charlson comorbidity
index [15], McCabe index [16] and systemic inflamma-
tory response syndrome (SIRS) parameters were prospec-
tively recorded on a standardised case report form. After
discharge, all prospectively collected data were verified
and completed by chart review. In addition, data on
microbiological investigations were retrieved from the
microbiology lab's internal computer system. Each case
report form with the corresponding chart was reviewed
together by two of the authors (J.M., S.B.), who assessed
the adequacy of empirical and adjusted antibiotic therapy
by consensus. Prescribing was reviewed daily and the
appropriateness of the antibiotic, the dose and route of
administration were assessed at any time during the
course of therapy.
The empirical antibiotic therapy was defined as the initial
antibiotic regimen started within 24 hours of admission.
The adjusted antibiotic therapy was the antibiotic regimen
after the first change of antibiotic substance. The switch ofBMC Infectious Diseases 2007, 7:21 http://www.biomedcentral.com/1471-2334/7/21
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the same antibiotic from i.v. to p.o. was not considered to
be an adjustment of therapy. Finally, we defined an anti-
biotic therapy as inadequate when one or more of the fol-
lowing points were not in accordance with local written
recommendations or published guidelines (e.g. The San-
ford Guide to Antimicrobial Therapy, practice guidelines
of the Infectious Diseases Society of America): spectrum,
dosage, application modus of antibiotics, or the duration
of therapy, and/or when pathogenic bacteria that were
resistant to the antibiotic used were isolated. If the appli-
cation modus was considered to be not appropriate, the
reason was recorded as "insufficient dosage" (e.g. if a
patient with catheter-related bloodstream infection
caused by S. aureus was treated with amoxicillin/clavu-
lanate p.o.), or "excessive dosage" (e.g. if a patient with
uncomplicated pneumonia caused by susceptible S. pneu-
moniae was kept on penicillin i.v.).
Statistical Methods
For the univariate analyses, t-tests between continuous
variables and Chi-squared tests (or Fisher's Exact tests
when appropriate) between categorical variables were
used. All associations found to be statistically significant
at the 25% significance level in the univariate analysis
were collectively considered for the multivariate analysis
to produce a model for both the empirical antibiotic ther-
apy and adjusted antibiotic therapy separately. The multi-
variate analysis used a logistic regression model with an
underlying binomial distribution with the Logit link. The
goodness of fit of the model was assessed with the Log
likelihood ratio test. The covariates considered for the
empirical antibiotic therapy multivariate analysis were
gender, age, neurological ward, involvement of infectious
disease consultants, renal failure, use of broad-spectrum
antibiotics, and superficial skin infections. For the
adjusted antibiotic therapy multivariate analysis the fol-
lowing were considered: switch of antibiotic therapy due
to bacteriological lab results, involvement of infectious
disease consultants and patients with respiratory tract
infections; however, none of these variables were found to
be of importance in the final model. Confounders and
plausible interactions considered were found not to be
statistically significant for entry into the model. All statis-
tical analyses were carried out using SAS version 8.2 (SAS
Institute Inc., Cary, NC, USA).
The study was approved by the Research Ethics Commit-
tee of the Cantons Basel-Stadt and Basel-Land (N. 226/
03).
Results
During the nine-month study period a total of 7792
patients were admitted to the University Hospital Basel
through the emergency department. Of these patients,
3387 were admitted during the weeks when the study was
carried out. Referral to another hospital within 48 hours
after admission led to the exclusion of 224 patients. Refer-
ral to the psychiatry, dermatology, gynecology/obstetrics
or otorhinolaryngology wards led to the exclusion of 88
patients, and 132 patients were excluded since they were
given therapeutic antibiotics prior to admission in an out-
patient setting (all these 132 patients had received antibi-
otics p.o.). A total of 572 of the remaining 2943 patients
(19.4%) were given therapeutic antibiotics within 24
hours after admission. Incomplete or missing records led
to the exclusion of 33 patients. The remaining 539
patients (94.2%) were analyzed. Data on demographics,
infectious diseases diagnosed on admission, and the serv-
ice in charge of these patients are presented in Table 1.
Bacteriological investigations
Within 48 hours of admission a total of 716 bacteriologi-
cal samples were taken from 438 patients (81.3%). The
most commonly performed investigations were blood
cultures (333 patients, 61.8% of all patients), urine cul-
tures (181, 33.6%) and cultures of sputum or broncho-
alveolar lavage (86, 16.0%). Two-hundred and fourteen
pathogenic bacterial isolates were identified in 183
patients. The most common were Escherichia coli (64
patients, 12%), Staphylococcus aureus (27 patients, 5%),
Streptococcus pneumoniae (23 patients, 4%), Klebsiella pneu-
moniae  (12 patients, 2.2%), Haemophilus influenzae (9
patients, 1.7%) and Pseudomonas aeruginosa (9 patients,
1.7%).
Antibiotic therapies
The most commonly used antibiotic for both empirical
and adjusted therapy was amoxicillin/clavulanate (Table
2). Broad-spectrum antibiotics (cefepime, imipenem,
meropenem, piperacillin/tazobactam) or vancomycin
were initially administered to 95 patients (17.6%). Empir-
ical antibiotic therapies lasted a mean of 7.5 days after
admission. 421 (83.7%) patients received at least one
antibiotic intravenously. Empirical intravenous antibiot-
ics were switched to oral administration a median of 4
days after admission (range: 0 – 43; Interquartile range:
3). The empirical therapy was adjusted in 168 patients
(31.2% of all included patients) (Table 2). Of these, 65
patients (38.7%) had their antibiotics switched because of
bacteriological results.
Empirical antibiotic therapy was inadequate in 121
patients (22.4%) and the adjusted antibiotic therapy was
inadequate in 46 of 168 patients (27.4%). In both empir-
ical and adjusted antibiotic therapy the most common
reason for inadequacy was the use of antibiotics with a too
broad spectrum (Table 3). The second most common rea-
son for inadequate adjusted therapy was the use of antibi-
otics ineffective against isolated pathogenic bacteria orBMC Infectious Diseases 2007, 7:21 http://www.biomedcentral.com/1471-2334/7/21
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against bacteria to be expected according to the postulated
infections, or the continuation of antibiotic therapy even
after negative cultures ruled out an infection (e.g. in the
case of assumed urinary tract infections).
Risk factors for inadequate antibiotic therapy
The univariate analysis of characteristics of patients receiv-
ing adequate or inadequate therapy is presented in Tables
4 and 5. In the multivariate analysis, inadequate empirical
antibiotic treatment was associated with female sex (odds
ratio for adequate treatment: 0.47, 95% confidence inter-
val 0.31–0.72), no infectious disease diagnosis (OR 0.08,
95% CI 0.01–0.78), the use of antibiotic therapies con-
taining vancomycin or broad-spectrum antibiotics
(cefepime, imipenem, meropenem, piperacillin/tazo-
bactam) (OR 0.42, 95% CI 0.26–0.70) and the presence
of renal failure (OR 0.58, 95% CI 0.36–0.92). Adequate
adjusted antibiotic treatment was associated with antibi-
otic switch due to bacteriological results (OR 5.13, 95%
CI 2.13–12.37).
Discussion
The main findings of this study were that I) 19% of
patients admitted through the emergency department
received antibiotics empirically. II) Empirical antibiotic
therapy was inadequate in 22% and adjusted antibiotic
therapy in 27% of cases. III) The main reason for inade-
quacy was the use of antibiotics with an unnecessarily
Table 1: Characteristics of the 539 included patients.
Characteristic Number of patients (n = 539) Percentage of all patients
Males 297 55.1%
Age in years (median; range) 69 [17–100]
17 to 40 years 96 17.8%
41 to 60 years 104 19.3%
More than 60 years 339 62.9%
Ward a
Medicine and geriatrics 359 66.6%
Surgery 173 32.1%
Medical intensive care 25 4.6%
Surgical intensive care 10 1.9%
Neurology 4 0.7%
Main infectious disease diagnosis upon admission
Respiratory tract infections 169 31.4%
Urinary tract infections, prostatitis, epididimytis 113 21.0%
Gastrointestinal infections b 81 15.0%
Skin and soft tissue infections 42 7.8%
Biliary tract infections 25 4.6%
Suspected systemic infections without identified focus c 25 4.6%
Sepsis d 22 4.1%
Bone and joint infections 17 3.2%
Ear, nose and throat infections 15 2.8%
Central nervous system infections 11 2.0%
Neutropenic fever 10 1.9%
Other 5 0.9%
No infectious disease diagnosis 4 0.7%
Total number of patients with SIRS e 256 47.5%
Charlson comorbidity index [15] (mean +/-SD) 2.4 (+/- 2.3)
McCabe index [16] - not fatal 443 82.2%
McCabe index - fatal < 5 years 64 11.9%
McCabe index - fatal < 6 months 32 5.9%
Died in hospital 31 5.8%
a If patients were on more than one ward, each ward was counted separately.
b Includes gastroenteritis, diverticulitis, peritonitis, enterocolitis, appendicitis, abdominal abscess, acute abdomen.
c These patients did not meet the criteria of the sepsis definition.
d Sepsis: defined as clinical evidence of infection, plus SIRSe.
e Systemic inflammatory response syndrome (SIRS): includes two or more of the following: temperature > 38°C or < 36°C, heart rate > 90 beats 
per minute, leukocytes > 12,000/µL or < 4,000/µL (band forms were not routinely determined and were therefore not considered), respiratory rate 
> 20 per minute.BMC Infectious Diseases 2007, 7:21 http://www.biomedcentral.com/1471-2334/7/21
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broad spectrum. Finally, IV) we identified risk factors for
inadequate empirical antibiotic treatment, such as female
sex or renal failure.
I) Antibiotic utilization rate
We found that 19.4% of medical and surgical patients
admitted through the emergency department to a Swiss
university hospital are started on therapeutic antibiotics
within 24 hours of admission. This antibiotic utilization
rate is similar to rates reported for medical admissions to
an Acute Medicines Assessment Unit in Aberdeen, Scot-
land (17%) [8], and to the prevalence of in-patients
treated with antibiotics in a Norwegian university hospital
(16.6%) [17] and in 8 Swiss non-university hospitals
(25%) [9]. Higher antibiotic utilization rates (45.5%)
have been previously reported for example from Italian
hospitals [18]. However, 84% of patients started on anti-
biotics in the present study received them in intravenous
form, compared to 60% of patients in the Aberdeen study
[8].
II) Inadequacy of antibiotic therapies
The empirical antibiotic therapy was inadequate in 22.4%
of our patients. The rate of inadequate treatments among
adjusted antibiotic therapies was even higher: 27.4%.
These inadequacy rates compare favourably with pub-
lished data indicating that as many as 41% to 91% of all
antibiotic prescriptions in hospitals are inappropriate
[11]. In the Aberdeen study for example, empirical ther-
apy was in accordance with the hospital's antibiotic policy
in only 52% of patients [8]. In a recent study in a 650-bed
hospital in Cleveland, Ohio, 30% of days of antibiotic
therapy were deemed unnecessary [7]. Finally, the study
examining the rate of inappropriate antibiotic use at 8
medium-sized Swiss hospitals found that 47% of patients
not seen by infectious disease consultants had inappropri-
ate antibiotic treatment [9].
Thus, inadequate use of antibiotics in our patients does
not appear to be more frequent than at other institutions,
despite the fact that no restrictive measures regarding anti-
biotic use are in place at our hospital. The relatively low
rate of inadequate antibiotic therapies in this study might
be explained by several factors. On one hand, patients on
antibiotic prophylaxis were excluded from the present
study, and inadequacy rates for antibiotic prophylaxis are
frequently higher than for therapy [9]. On the other hand,
differences in the populations studied and in hospital's
characteristics may play a role. In this sense, three charac-
teristics of our hospital may be relevant: first, an infectious
Table 2: Most frequently used empirical and adjusted antibiotic therapies
Type of therapy Number of patients %
Empirical antibiotic therapies 539 100%
Amoxicillin/clavulanate 223 41.4%
Ciprofloxacin 88 16.3%
Piperacillin/tazobactam 55 10.2%
Amoxicillin/clavulanate + clarithromycin 33 6.1%
Ceftriaxone 23 4.3%
Cefepime + amikacin 18 3.3%
Amoxicillin/clavulanate + amikacin 12 2.2%
Ciprofloxacin + metronidazole 9 1.7%
Trimethoprim/sulfamethoxazole 6 1.1%
Norfloxacin 6 1.1%
Cefepime 5 0.9%
Ceftriaxone + clarithromycin 5 0.9%
Other antibiotics or antibiotic combinations 56 10.4%
Adjusted antibiotic therapies 168 100%
Amoxicillin/clavulanate 29 17.3%
Piperacillin/tazobactam 22 13.1%
Ciprofloxacin 15 8.9%
Penicillin 12 7.1%
Amoxicillin/clavulanate + ciprofloxacin 8 4.8%
Amoxicillin/clavulanate + clarithromycin 6 3.6%
Meropenem 5 3.0%
Cefuroxime 5 3.0%
Other antibiotics or antibiotic combinations a 66 39.3%
a e.g.: ceftriaxone (4 patients), flucloxacillin (3), amoxicillin (3), levofloxacin (3), ciprofloxacin + metronidazole (3), ciprofloxacin + rifampicin (2), 
cefepime (2), cefepime + tobramycin (2), clindamycin (2), trimethoprim/sulfamethoxazole (2), imipenem/cilastatin (2), vancomycin (2), ceftriaxone + 
rifampicin (2), cefuroxime + clarithromycin (2).BMC Infectious Diseases 2007, 7:21 http://www.biomedcentral.com/1471-2334/7/21
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diseases consultation service which has access to all wards
of the hospital and which provides consultations with an
"academic detailing" approach (each consultation is dis-
cussed in a direct conversation with the intern or resident
in charge, providing a targeted one-on-one education) ;
second, a close collaboration between infectious diseases
department and microbiology laboratory (e.g. one micro-
biologist participates in the daily meeting of the infectious
diseases department, where all patients seen by the infec-
tious diseases consultants are discussed and all positive
blood cultures are reviewed); and third, the clinical liai-
son between laboratory and ward through the infectious
diseases consultants, who follow-up all positive blood
cultures contacting the physicians in charge on the ward
and providing oral clinical advice and, if requested, writ-
ten consultation. Indeed, each one of these interventions
has been shown to improve the use of antibiotics
[13,19,20].
III) Reasons for inadequate adjusted therapies
Despite the interventions mentioned above, the rate of
inadequate adjusted therapies in our study was even
higher than the rate of inadequate empirical therapies.
The main reason for inadequacy of adjusted therapies was
the unnecessary use of broad-spectrum antibiotics. This
happened frequently because persistent fever after only 24
to 48 hours of empirical antibiotic therapy was considered
to be caused by resistant bacteria, and empirical antibiot-
ics were unnecessarily switched to broad-spectrum antibi-
otics. The second most common reason for inadequacy
was the use of antibiotics that were ineffective against iso-
lated pathogenic bacteria or bacteria to be expected
according to the identified focus of infection, or the con-
tinuation of antibiotic therapy even after an infection was
ruled out by negative culture results (e.g. in the case of
postulated urinary tract infections). The failure to adapt
therapy to culture results suggests that microbiological
investigations had an insufficient impact on the manage-
ment of patients. A similar problem was observed in the
Aberdeen study, where in 55% of patients with clinically
significant culture results and an inappropriate empirical
regimen, the medication was not changed to a more
appropriate antibiotic [8]. Furthermore, researchers at the
University of Iowa Hospitals and Clinics have previously
shown that the reporting of antibiotic susceptibility test-
ing data of positive blood cultures had only a limited
impact on antimicrobial management of patients with
bloodstream infections [21]. These observations confirm
that the reassessment of empirical therapy after 2–4 days,
when most culture results are available and clinical evolu-
tion is assessable, is crucial. Counselling of prescribers at
this stage appears to be essential and is more likely to be
efficacious than at an earlier stage [22,23].
IV) Risk factors for inadequate therapy
Most factors identified in the present study by multivari-
ate analysis as being associated with adequate or inade-
quate antibiotic therapy are not surprising. Antibiotic
therapy was more frequently inadequate in patients with
renal failure (mainly because of difficulties in establishing
the correct dose), and in patients where no infectious dis-
ease was identified or postulated (and where antibiotics
Table 3: Reasons for inadequacy of empirical and adjusted antibiotic therapies
Reason for inadequacy a Number of patients %
Empirical antibiotic therapies 539
Inadequate empirical therapy 121 100%
Spectrum too broad 29 24.0%
Inadequate duration 28 23.1%
Insufficient dosage 27 22.3%
Spectrum too narrow 22 18.2%
Wrong spectrum/inadequate use b 21 17.4%
Excessive dosage 3 2.5%
Adjusted antibiotic therapies 168
Inadequate adjusted therapy 46 100%
Spectrum too broad 24 52.2%
Wrong spectrum/inadequate use c 12 26.1%
Insufficient dosage 7 15.2%
Inadequate duration 2 4.4%
Excessive dosage 1 2.2%
Spectrum too narrow 1 2.2%
a More than one reason may apply for each patient.
b If antibiotic given covered completely different spectrum than expected bacteria would require or no antibiotic therapy was warranted.
c If bacteriological results had shown that identified bacteria were resistant to antibiotics used, or antibiotic covered completely different spectrum 
than expected bacteria would require or no antibiotic therapy was warranted.BMC Infectious Diseases 2007, 7:21 http://www.biomedcentral.com/1471-2334/7/21
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Table 4: Characteristics of patients receiving adequate or inadequate empirical antibiotic treatment (univariate analysis).
Characteristic Patients (n) receiving 
adequate empirical 
antibiotic treatment
Patients (n) receiving 
inadequate empirical 
antibiotic treatment
p-value OR (95% CI) for adequate 
therapy
Number of patients 418 (77.6%) 121 (22.4%)
Women 170 (70.2%) 72 (29.8%) < 0.001 0.47 (0.31–0.70)
Age
Median age and range (years) 67 [18–100] 72 [17–97] 0.038*
< 40 years 74 (77.1%) 22 (22.9%) 0.904 0.97 (0.57–1.64)
41 – 60 yr. 91 (87.5%) 13 (12.5%) 0.007 2.31 (1.12–4.30)
> 60 years 253 (74.6%) 86 (25.4%) 0.034 0.62 (0.40–0.97)
Ward:
Medicine/Geriatrics 281 (78.3%) 78 (21.7%) 0.399 1.19 (0.80–1.76)
Surgery 135 (78.9%) 36 (21.1%) 0.733 1.09 (0.70–1.65)
Medical and surgical intensive care 25 (71.4%) 10 (28.6%) 0.408 0.73 (0.34–1.55)
Neurology 1 (25.0%) 3 (75.0%) 0.040† 0.10 (0.01–0.94)
Died in hospital 25 (80.6%) 6 (19.4%) 0.671 1.22 (0.49–3.04)
Charlson index:
Charlson index total 0 110 (81.5%) 25 (18.5%) 0.206 1.37 (0.84–2.24)
Charlson index total 1 – 5 264 (75.9%) 84 (24.1%) 0.205 0.76 (0.49–1.17)
Charlson index total > 5 44 (78.6%) 12 (21.4%) 0.845 1.07 (0.55–2.10)
McCabe index:
Not fatal 343 (77.4%) 100 (22.6%) 0.882 0.96 (0.56–1.64)
Fatal (< 5 years) 52 (81.3%) 12 (18.8%) 0.450 1.29 (0.67–2.51)
Fatal (< 6 months) 23 (71.9%) 9 (28.1%) 0.428 0.73 (0.33–1.61)
Number of microbiological exams 
performed:
None 78 (77.2%) 23 (22.8%) 0.931 0.98 (0.58–1.64)
One or more 340 (77.6%) 98 (22.4%) 0.931 1.02 (0.61–1.71)
Infectious diseases consultants involved:
Within 24 hours 23 (62.2%) 14 (37.8%) 0.020 0.45 (0.22–0.89)
Were involved 58 (69.0%) 26 (31.0%) 0.042 0.59 (0.35–0.99)
Therapy adjusted 128 (76.2%) 40 (23.8%) 0.611 0.89 (0.58–1.38)
Hepatic failure reported 1 (50.0%) 1 (50.0%) 0.399† 0.29 (0.02–4.64)
Renal failure reported 100 (69.0%) 45 (31.0%) 0.004 0.53 (0.35–0.82)
Received broad-spectrum antibiotics or 
vancomycin
62 (65.3%) 33 (34.7%) 0.002 0.46 (0.29–0.75)
Allergy to antibiotics reported 29 (70.1%) 12 (29.9%) 0.276 0.68 (0.33–1.37)
Diagnoses
Biliary tract infections 19 (76.0%) 6 (24%) 0.849 0.91 (0.36–2.34)
Bone and joint infections 12 (70.6%) 5 (29.4%) 0.553† 0.69 (0.24–1.99)
Central nervous system infections 9 (81.8%) 2 (18.1%) 1.000† 1.31 (0.28–6.14)
Ear, nose and throat infections 11 (73.3%) 4 (26.7%) 0.753† 0.79 (0.25–2.53)
Gastrointestinal infections 59 (73.8%) 21 (26.3%) 0.377 0.78 (0.45–1.35)
Neutropenic fever 10 (100%) 0 (0.00%) 0.127† N/A
No infectious disease 1 (25.0%) 3 (75.0%) 0.037† 0.09 (0.01–0.92)
Respiratory tract infections 139 (82.2%) 30 (17.8%) 0.077 1.51 (0.95–2.39)
Sepsis 19 (86.4%) 3 (13.6%) 0.436† 1.87 (0.55–6.44)
Skin and soft tissue infections 48 (81.4%) 11 (18.6%) 0.458 1.30 (0.65–2.58)
Suspected systemic infections without 
identified focus
19 (76.0%) 6 (24.0%) 0.849 0.91 (0.36–2.34)
Urinary tract infections, prostatitis, 
epididimytis
83 (73.5%) 30 (26.6%) 0.240 0.75 (0.47–1.21)
Other 11 (68.8%) 5 (31.3%) 0.371† 1.30 (0.21–1.84)
SIRS present 199 (77.7%) 57 (22.3%) 0.923 1.02 (0.68–1.53)
Note: The adequacy of treatment was compared against the individual variables with the Chi-squared test with odds ratio production
* Wilcoxon-Mann-Whitney test
† Fisher's Exact testBMC Infectious Diseases 2007, 7:21 http://www.biomedcentral.com/1471-2334/7/21
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Table 5: Characteristics of patients receiving adequate or inadequate adjusted antibiotic treatment (univariate analysis)
Characteristic Patients (n) receiving 
adequate adjusted 
antibiotic treatment
Patients (n) receiving 
inadequate adjusted 
antibiotic treatment
p-value OR (95% CI) for adequate 
therapy
Number of patients 121 (72.5%) 46 (27.5%)
Women 54 (70.1%) 23 (29.9%) 0.534 0.81 (0.41–1.59)
Age
Median age and range (years) 65 [21–97] 70 [19–95] 0.115*
< 40 22 (78.6%) 6 (21.4%) 0.427 1.48 (0.56–3.93)
41 – 60 29 (80.6%) 7 (19.4%) 0.219 1.76 (0.71–4.35)
> 60 70 (68.0%) 33 (32.0%) 0.099 0.54 (0.26–1.13)
Ward:
Medicine/Geriatrics 85 (72.0%) 33 (28.0%) 0.472 0.77 (0.38–1.56)
Surgery 36 (73.5%) 13 (26.5%) 0.955 0.98 (0.47–2.06)
Medical and surgical intensive care 13 (86.7%) 2 (13.3%) 0.360† 2.45 (0.53–11.28)
Neurology 0 (0.0%) 0 (0.0%) N/A N/A
Died in hospital 10 (90.9%) 1 (9.1%) 0.293† 4.05 (0.50–32.60)
Reason for switch:
Switch due to bacterial lab results 58 (89.2%) 7 (10.7%) < 0.001 5.13 (2.13–12.37)
Switch due to other reason 43 (64.2%) 24 (35.8%) 0.050 0.51 (0.25–1.01)
Charlson Index:
Charlson index total 0 26 (76.5%) 8 (23.5%) 0.557 1.30 (0.54–3.13)
Charlson index total 1 – 5 84 (71.8%) 33 (28.2%) 0.770 0.89 (0.42–1.89)
Charlson index total > 5 11 (68.8%) 5 (31.2%) 0.771† 0.82 (0.27–2.50)
McCabe index
Not fatal 97 (74.0%) 34 (26.0%) 0.380 1.43 (0.64–3.16)
Fatal (< 5 years) 18 (75.0%) 6 (25.0%) 0.763 1.17 (0.43–3.15)
Fatal (< 6 months) 6 (50.0%) 6 (50.0%) 0.055† 0.35 (0.11–1.14)
Number of microbiological exams 
performed:
None 13 (76.5%) 4 (23.5%) 0.783† 1.26 (0.39–4.10)
One or more 108 (72%) 42 (28%) 0.783† 0.79 (0.24–2.57)
Infectious diseases consultants involved:
Within 24 hours 22 (88.0%) 3 (12.0%) 0.059 3.19 (0.91–11.21)
Were involved 52 (82.5%) 11 (17.5%) 0.023 2.40 (1.11–5.16)
Hepatic failure reported 1 (100.0%) 0 (0.0%) 1.000† N/A
Renal failure reported 34 (70.8%) 14 (29.2%) 0.766 0.89 (0.43–1.88)
Received broad-spectrum antibiotics or 
vancomycin
37 (84.1%) 7 (15.9%) 0.520 1.28 (0.60–2.72)
Allergy to antibiotics reported 9 (64.3%) 5 (35.7%) 0.534† 0.66 (0.21–2.08)
Diagnoses
Biliary tract infections 5 (83.3%) 1 (16.7%) 1.000† 1.94 (0.22–17.06)
Bone and joint infections 10 (100.0%) 0 (0.0%) 0.063† N/A
CNS infections 3 (100.0%) 0 (0.0%) 0.562† N/A
Ear, nose and throat infections 0 (0.00%) 1 (100%) 0.275† N/A
Gastrointestinal infections 17 (63.0%) 10 (37.0%) 0.228 0.59 (0.25–1.40)
Urinary tract infections, postatitis, 
epididimytis
21 (67.7%) 10 (32.3%) 0.52 0.76 (0.33–1.76)
Neutropenic fever 6 (85.7%) 1 (14.3%) 0.675† 2.35 (0.28–20.05)
Respiratory tract infections 34 (60.7%) 22 (39.3%) 0.016 0.43 (0.21–0.86)
Sepsis 12 (92.3%) 1 (7.7%) 0.116† 4.95 (0.63–39.24)
Skin and soft tissue infections 10 (71.4%) 4 (28.6%) 1.000† 0.95 (0.28–3.18)
Suspected systemic infections without 
identified focus
5 (71.4%) 2 (28.6%) 1.000† 0.95 (0.18–5.07)
Other 8 (88.9%) 1 (11.1%) 0.447† 3.19 (0.39–26.21)
* Wilcoxon-Mann-Whitney test
† Fisher's Exact testBMC Infectious Diseases 2007, 7:21 http://www.biomedcentral.com/1471-2334/7/21
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were usually started only because of fever). In contrast, a
change of antibiotic therapy according to results of micro-
biological investigations was associated with adequate
therapy. The association between use of broad-spectrum
antibiotics or vancomycin and inadequate empirical ther-
apy confirms that the use of these medications is often
unjustified. It is more difficult to explain why women
were less likely to receive adequate empirical antibiotic
treatment than men. Gender differences in the prescrip-
tion of treatment or prophylaxis have previously been
reported, e.g. for cardiovascular diseases and HIV-infec-
tion [24-27]. To our knowledge however, only one previ-
ous study reported that rates of antibiotic use were
influenced by gender (females in one New Zealand town
received antibiotics more often than males) [28]. This
study found also a strong relationship between socioeco-
nomic status and antibiotic dispensing. In our study,
women were slightly older than men (mean age ± stand-
ard deviation: 65.5 ± 20.4 years, versus 62.3 ± 19.6), and
age over 60 years was associated with inadequate empiri-
cal antibiotic treatment in univariate analysis. We cannot
speculate on the role of socioeconomic status, since we
did not collect information on this factor.
The impact of infectious diseases consultations was con-
sidered by recording whether infectious diseases consult-
ants were involved within 24 hours of admission or
whether they were involved at all. In the univariate analy-
sis involvement of infectious diseases consultants was sig-
nificantly associated with inadequate empirical therapy
(Tab. 4). This can be explained by the fact that consulta-
tion is usually required for patients with more severe or
difficult to manage infections or with unclear clinical
presentation, who are usually started on empirical antibi-
otic therapy before the infectious diseases consultation is
obtained, in order to avoid delays. Thus, adjusted thera-
pies may show more reliably what the effect of infectious
diseases consultations was. Indeed, involvement of infec-
tious diseases consultants was associated with adequate
adjusted therapy (Tab. 5) in univariate analysis.
The present study has several limitations. In particular,
patients started on antibiotics more than 24 hours after
admission or who received only antibiotic prophylaxis,
patients admitted directly to the wards, and patients who
received therapeutic oral antibiotics as out-patients were
not included in the study. In addition, only surgical, med-
ical, geriatric, and neurological patients were evaluated.
Also, we did not investigate the relationship between ade-
quacy or inadequacy of treatment and clinical outcomes
other than in-hospital death. However, this study has also
several strengths. Clinical data were raised and evaluated
consistently and prospectively in a large defined patient
population, and patients were followed until discharge.
Furthermore, a large part of in-patients at our hospital, as
at other hospitals, are admitted through the emergency
department. Hence, our results are clinically relevant for
this setting.
Conclusion
In conclusion, despite the absence of a restrictive antibi-
otic policy, the rate of inadequate antibiotic therapies at
our hospital was similar to rates reported from other insti-
tutions. This suggests that restrictions in the antibiotic use
are not an absolutely necessary component of an antibi-
otic stewardship approach based mainly on multidiscipli-
nary collaboration, education and close clinical liaison
with the bacteriology laboratory. Nevertheless, the
present study demonstrated a significant overuse of anti-
biotics, especially broad-spectrum antibiotics and intrave-
nous antibiotics, and an insufficient consideration of
microbiological results. Surprisingly, adjusted antibiotic
therapies were more frequently inappropriate than empir-
ical therapies. Thus, interventions aiming at improving
antibiotic prescribing should focus on both initial empir-
ical therapy and streamlining and adjustment of therapy.
Furthermore, the impact of microbiological results on the
clinical management of patients should be improved.
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